Masimo
pharmaMasimo Corporation, established in 1989 and headquartered in Irvine, California, is a global leader in developing, manufacturing, and marketing non-invasive physiological monitoring technologies and hospital automation systems. A cornerstone of their offerings is the Masimo SET pulse oximetry, engineered to overcome the limitations of conventional oximeters by accurately measuring through patient motion and low perfusion. Their advanced Masimo rainbow SET platform further expands capabilities, providing non-invasive monitoring of various hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, respiration rate, hemoglobin concentration, carboxyhemoglobin, and methemoglobin, alongside arterial oxygen saturation and calculated oxygen content and reserve index. Beyond oxygenation, Masimo provides SedLine technology for brain function monitoring via EEG, a diverse range of capnography and gas monitoring products (including external, integrated, and handheld devices), O3 regional oximetry for localized tissue oxygen saturation, and comprehensive hemodynamic monitoring solutions. The company also offers the Masimo Hospital Automation platform, encompassing solutions like Patient SafetyNet and UniView, along with connectivity devices, and nasal high-flow ventilation and neuromodulation systems. Masimo distributes its products worldwide through a direct sales force, distributors, and OEM partners, serving a broad spectrum of clients including hospitals, emergency medical services, home care providers, long-term care facilities, physician offices, veterinarians, and directly to consumers for personal health products via its masimopersonalhealth.com e-commerce site.
MASI Stock Price
Recent News
